Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Gemcitabine Plus Pegylated Liposomal Doxorubicin in Patients with Advanced Epithelial Ovarian Cancer Resistant/Refractory to Platinum and/or Taxanes. A HeCOG Phase II Study

DIMOSTHENIS V. SKARLOS, HARALABOS P. KALOFONOS, GEORGE FOUNTZILAS, MELETIOS A. DIMOPOULOS, NICHOLAS PAVLIDIS, EVANGELIA RAZIS, THEOFANIS ECONOMOPOULOS, DIMITRIOS PECTASIDES, HELEN GOGAS, PARIS KOSMIDIS, DIMITRIOS BAFALOUKOS, GEORGE KLOUVAS, GEORGE KYRATZIS and GERASIMOS ARAVANTINOS
Anticancer Research July 2005, 25 (4) 3103-3108;
DIMOSTHENIS V. SKARLOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hecogiat@otenet.gr
HARALABOS P. KALOFONOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGE FOUNTZILAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MELETIOS A. DIMOPOULOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICHOLAS PAVLIDIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EVANGELIA RAZIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THEOFANIS ECONOMOPOULOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIMITRIOS PECTASIDES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HELEN GOGAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PARIS KOSMIDIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIMITRIOS BAFALOUKOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGE KLOUVAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGE KYRATZIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GERASIMOS ARAVANTINOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory advanced epithelial ovarian cancer (AEOC). Patients and Methods: Patients (pts), who had been treated with platinum or paclitaxel and met the criteria of resistant/refractory AEOC, received GEM 650 mg/m2 days 1 and 8 and PLD 25 mg/m2 day 1 every 4 weeks up to a total of 6 cycles, unless disease progression or adverse effects prohibited further therapy. Results: Thirty-seven patients entered the study. There was 1 complete (3%) and 7 partial responses (19%) for an overall response rate of 22%. Two patients had stable disease (5.5%). After a median follow-up of 16.2 months, the median survival was 8.4 months and time to treatment failure 2.7 months. The most frequent severe toxicity was myelosuppression recorded in 13 (35%) patients. Severe stomatitis was recorded in only 2 (5%) cases and severe palmar-plantar erythrodysesthesia in 1 patient. One severe allergic reaction (grade 4) to PLD was recorded following the third cycle of treatment. Conclusion: The combination of GEM and PLD in patients with AEOC, who are resistant/refractory to platinum and/or Taxanes, did not show any superiority over monotherapy. However, in view of the acceptable toxicity profile, the above combination may deserve further investigation in a randomised setting.

  • Pegylated liposomal doxorubicin
  • Gemcitabine
  • ovarian cancer

Footnotes

  • Received January 4, 2005.
  • Accepted May 5, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (4)
Anticancer Research
Vol. 25, Issue 4
1 Jul 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Gemcitabine Plus Pegylated Liposomal Doxorubicin in Patients with Advanced Epithelial Ovarian Cancer Resistant/Refractory to Platinum and/or Taxanes. A HeCOG Phase II Study
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
14 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Gemcitabine Plus Pegylated Liposomal Doxorubicin in Patients with Advanced Epithelial Ovarian Cancer Resistant/Refractory to Platinum and/or Taxanes. A HeCOG Phase II Study
DIMOSTHENIS V. SKARLOS, HARALABOS P. KALOFONOS, GEORGE FOUNTZILAS, MELETIOS A. DIMOPOULOS, NICHOLAS PAVLIDIS, EVANGELIA RAZIS, THEOFANIS ECONOMOPOULOS, DIMITRIOS PECTASIDES, HELEN GOGAS, PARIS KOSMIDIS, DIMITRIOS BAFALOUKOS, GEORGE KLOUVAS, GEORGE KYRATZIS, GERASIMOS ARAVANTINOS
Anticancer Research Jul 2005, 25 (4) 3103-3108;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Gemcitabine Plus Pegylated Liposomal Doxorubicin in Patients with Advanced Epithelial Ovarian Cancer Resistant/Refractory to Platinum and/or Taxanes. A HeCOG Phase II Study
DIMOSTHENIS V. SKARLOS, HARALABOS P. KALOFONOS, GEORGE FOUNTZILAS, MELETIOS A. DIMOPOULOS, NICHOLAS PAVLIDIS, EVANGELIA RAZIS, THEOFANIS ECONOMOPOULOS, DIMITRIOS PECTASIDES, HELEN GOGAS, PARIS KOSMIDIS, DIMITRIOS BAFALOUKOS, GEORGE KLOUVAS, GEORGE KYRATZIS, GERASIMOS ARAVANTINOS
Anticancer Research Jul 2005, 25 (4) 3103-3108;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Cisplatin-Ifosfamide-Gemcitabine as Salvage Chemotherapy in Ovarian Cancer Patients Pretreated with Platinum Compounds and Paclitaxel
  • A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer
  • Google Scholar

More in this TOC Section

  • Primary Synovial Sarcoma of the Bone: A Case Report and Literature Review
  • Melanoma of the Lower Limbs and Hips: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019
  • Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire